Latest news

Thumbnail image for Gilead to buy Immunomedics for $21bn

Gilead to buy Immunomedics for $21bn

The move adds Trodelvy, a first-in-class antibody-drug conjugate approved to treat triple-negative breast cancer, to the drugmaker's portfolio

14th September 2020

Thumbnail image for NICE backs Portola's Ondexxya

NICE backs Portola's Ondexxya

The drug's use has, however, been restricted to reversing anticoagulation from apixaban or rivaroxaban in adults with life threatening or uncontrolled bleeding in the gastrointestinal tract

11th September 2020

Previous  --   5 6 7 8 9 10 11 12 13 14   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download